Veradermics, Incorporated (MANE) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Veradermics, Incorporated (MANE) trades at $109.49 with AI Score 59/100 (Grade B). Veradermics, Incorporated is a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. Market cap: $4.57B, Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for MANE: MANE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MANE against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
MANE: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Veradermics, Incorporated (MANE) Healthcare & Pipeline Overview
Veradermics, Incorporated, founded in 2019, is a biopharmaceutical company developing innovative dermatological and aesthetic treatments. Their pipeline focuses on addressing prevalent conditions like pattern hair loss and skin diseases, positioning them in the competitive biotechnology sector with a focus on unmet needs in dermatology.
What Is the Investment Thesis for MANE?
Veradermics, Incorporated presents a notable research candidate within the biotechnology sector, driven by its focus on dermatological and aesthetic conditions with significant unmet needs. The company's lead product, VDPHL01, targeting pattern hair loss, has the potential to capture a substantial market share. The development of VDMN, VDAA, and VDMC further diversifies the company's pipeline and reduces risk. However, the company's P/E ratio of -401.33 indicates it is not currently profitable. Key value drivers include successful clinical trials, regulatory approvals, and commercialization of its products. Upcoming clinical trial results for VDPHL01 will be a critical catalyst. Potential risks include clinical trial failures, regulatory hurdles, and competition from established players in the dermatology market.
Based on FMP financials and quantitative analysis
MANE Key Highlights
- Veradermics, Incorporated focuses on novel therapeutics for dermatologic and aesthetic conditions.
- The company's lead product, VDPHL01, is an oral, non-hormonal treatment for pattern hair loss.
- Veradermics is developing VDMN, a dissolvable microarray patch technology for immunotherapy of common warts.
- The company's pipeline includes VDAA for the treatment of alopecia areata and VDMC for molluscum contagiosum.
- Veradermics' P/E ratio is -401.33, reflecting its current lack of profitability as it invests in R&D.
Who Are MANE's Competitors?
MANE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABEO Abeona Therapeutics Inc. | $6.34 | -2.08% | $362M | 37 |
| DRMA Dermata Therapeutics, Inc. | $1.28 | +0.79% | 30 | |
| HELP Cybin Inc. | $7.11 | -1.93% | $356M | 48 |
| LSTA Lisata Therapeutics, Inc. | $3.52 | -1.95% | $32.1M | — |
| CAI Caris Life Sciences, Inc. | $15.56 | -5.64% | $4.40B | 79 |
| VCYT Veracyte, Inc. | $59.53 | +3.96% | $4.75B | 99 |
| ACAD ACADIA Pharmaceuticals Inc. | $25.43 | +1.36% | $4.35B | 81 |
| ELVN Enliven Therapeutics, Inc. | $54.47 | +5.42% | $3.89B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MANE's Key Strengths?
- Novel drug candidates targeting unmet needs in dermatology.
- Innovative drug delivery technologies (e.g., microarray patch).
- Experienced management team with expertise in drug development.
- Strong intellectual property portfolio.
What Are MANE's Weaknesses?
- Limited commercialization experience.
- Dependence on successful clinical trial outcomes.
- High research and development costs.
- Currently unprofitable with a negative P/E ratio.
What Could Drive MANE Stock Higher?
- Clinical trial results for VDPHL01 in pattern hair loss are expected in Q4 2026.
- Regulatory submissions for VDMN for the treatment of common warts are planned for H1 2027.
- Expansion of the company's research and development pipeline.
- Strategic partnerships with pharmaceutical companies.
What Are the Key Risks for MANE?
- Negative return on equity (-95.4%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures for any of the company's drug candidates.
- Regulatory delays or rejection of marketing applications.
- Competition from established pharmaceutical companies with greater resources.
- High research and development costs.
- Dependence on securing additional funding to support operations.
What Are the Growth Opportunities for MANE?
- Expansion into new therapeutic areas represents a significant growth opportunity for Veradermics. By leveraging its expertise in dermatological drug development, the company can explore treatments for other skin conditions, such as psoriasis, eczema, and skin cancer. The global market for psoriasis treatment alone is projected to reach $25 billion by 2028, offering a substantial revenue opportunity. This expansion would require further investment in research and development, but could significantly diversify the company's product portfolio and revenue streams.
- Geographic expansion into international markets presents another key growth opportunity. While Veradermics is currently based in the United States, the company can expand its reach by commercializing its products in Europe, Asia, and other regions. The global dermatology market is experiencing rapid growth, particularly in emerging economies, driven by increasing disposable incomes and a growing awareness of skin health. Entering these markets would require navigating different regulatory landscapes and establishing local partnerships, but could significantly increase the company's sales and profitability.
- Strategic partnerships and collaborations with other pharmaceutical companies and research institutions can accelerate the development and commercialization of Veradermics' products. By partnering with larger companies, Veradermics can gain access to additional resources, expertise, and distribution networks. These partnerships can also help to reduce the financial risk associated with drug development and increase the likelihood of regulatory approval. The biotechnology industry is characterized by a high degree of collaboration, and Veradermics can benefit from actively seeking out strategic alliances.
- Development of novel drug delivery systems can enhance the efficacy and patient compliance of Veradermics' products. The company's VDMN dissolvable microarray patch technology represents a promising approach to drug delivery, offering a non-invasive and convenient alternative to traditional injections. By continuing to invest in innovative drug delivery systems, Veradermics can differentiate its products from competitors and improve patient outcomes. The market for drug delivery systems is expected to grow significantly in the coming years, driven by the increasing demand for personalized medicine and patient-centric healthcare.
- Targeting pediatric dermatological conditions represents a largely untapped market with significant growth potential. Many skin conditions, such as atopic dermatitis and molluscum contagiosum, are common in children, but there are limited treatment options available. By developing safe and effective therapies specifically for pediatric patients, Veradermics can address a significant unmet need and capture a substantial share of this market. This would require conducting clinical trials in pediatric populations and obtaining regulatory approval for pediatric use, but could significantly expand the company's reach and impact.
What Opportunities Does MANE Have?
- Expansion into new therapeutic areas within dermatology.
- Geographic expansion into international markets.
- Strategic partnerships with larger pharmaceutical companies.
- Development of personalized medicine approaches.
What Threats Does MANE Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays in drug approval.
- Clinical trial failures.
- Changes in healthcare reimbursement policies.
What Are MANE's Competitive Advantages?
- Proprietary drug formulations and delivery systems.
- Patent protection for novel therapeutics.
- Clinical data supporting efficacy and safety.
- Established relationships with key opinion leaders in dermatology.
What Does MANE Do?
Veradermics, Incorporated, established in 2019 and headquartered in New Haven, Connecticut, is a biopharmaceutical company dedicated to the discovery and development of novel therapies for dermatologic and aesthetic conditions. The company's core focus lies in addressing unmet needs in the treatment of prevalent dermatological disorders affecting both adults and children. Veradermics' lead product, VDPHL01, is an oral, non-hormonal treatment designed for both men and women suffering from pattern hair loss (PHL), offering a chronic hair loss therapy option. Beyond VDPHL01, Veradermics is developing VDMN, a dissolvable microarray patch technology for the immunotherapy of common warts. The company is also advancing VDAA for the treatment of alopecia areata and VDMC for molluscum contagiosum. These products target a range of conditions, including androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. The company aims to establish itself as a leader in innovative dermatological treatments.
What Products and Services Does MANE Offer?
- Develop novel therapeutics for dermatologic conditions.
- Focus on treatments for pattern hair loss (PHL) in adults and children.
- Offer VDPHL01, an oral, non-hormonal treatment for PHL.
- Develop VDMN, a dissolvable microarray patch for common warts.
- Create VDAA for the treatment of alopecia areata.
- Formulate VDMC for the treatment of molluscum contagiosum.
How Does MANE Make Money?
- Develop and patent novel dermatological therapeutics.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA.
- Commercialize approved products through direct sales or partnerships.
What Industry Does MANE Operate In?
The biotechnology industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The dermatology market, in particular, is driven by an increasing prevalence of skin conditions and a growing demand for aesthetic treatments. Veradermics, Incorporated operates in this dynamic landscape, competing with both established pharmaceutical companies and emerging biotech firms.
Who Are MANE's Key Customers?
- Healthcare providers (dermatologists, physicians)
- Clinicians treating dermatologic conditions
- Adults and children with dermatologic conditions
- Medical and clinical research community
ROE -95%Key Financial Metrics
Return on equity for Veradermics, Incorporated stands at -95.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 59.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.1%, the inverse of the P/E and a quick read on earnings relative to price.
Veradermics, Incorporated (MANE) Valuation Context
Valued at $4.57B, MANE is classified as a mid-cap stock. Relative to its peer group, MANE's quantitative score of 59/100 is above the peer average of 49/100.
Company Profile
Veradermics, Incorporated operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New Haven, US. The company is led by CEO Reid Waldman. MANE has traded publicly since 2026.
FY2026 estForward Outlook
Wall Street analysts project Veradermics, Incorporated revenue of about $0 for fiscal 2026, with EPS near $-2.98.
MANE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- MANE's recent insider buying suggests strong confidence from those who know the company best. It's a signal they believe the stock is undervalued.
- The buzz in the community is optimistic about MANE's new product line, with many anticipating strong sales. This positive sentiment could drive demand.
- Market perception seems to be shifting favorably towards MANE, with more analysts highlighting its growth potential. This increased visibility could attract new investors.
- There's a growing consensus that MANE is well-positioned to capitalize on emerging market trends, potentially leading to significant revenue gains.
Bear Case
- Recent community chatter reveals concerns about increased competition in MANE's sector. This could squeeze margins and impact market share.
- Insider selling, although less prominent than buying, raises questions about short-term prospects. Some insiders might be cashing out for personal reasons, but it's worth noting.
- The overall market sentiment is cautious due to macroeconomic uncertainties, which could negatively impact MANE despite its specific strengths.
- Some community members are worried about potential regulatory hurdles for MANE's new products. These delays could affect the company's growth trajectory.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MANE Latest News
MANE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MANE.
Price Targets
Wall Street price target analysis for MANE.
MANE MoonshotScore
What does this score mean?
The MoonshotScore rates MANE 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Reid Waldman
CEO
Reid Waldman is the Chief Executive Officer of Veradermics, Incorporated. His background includes extensive experience in the biopharmaceutical industry, with a focus on dermatology and aesthetic medicine. Prior to joining Veradermics, he held leadership positions at several biotech companies, where he oversaw drug development programs and commercialization efforts. He holds an MBA from a top-tier business school and a Ph.D. in molecular biology.
Track Record: Under Reid Waldman's leadership, Veradermics has advanced its lead product, VDPHL01, into clinical trials and expanded its pipeline with the addition of VDMN, VDAA, and VDMC. He has also secured key partnerships with research institutions and raised significant capital to fund the company's growth. His strategic vision has positioned Veradermics as a leader in innovative dermatological treatments.
Veradermics, Incorporated Healthcare Stock: Key Questions Answered
What does the AI Score mean for MANE?
MANE holds an AI Score of 59/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Veradermics, Incorporated is a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. Their pipeline includes treatments for pattern hair …
What does Veradermics, Incorporated do?
Veradermics, Incorporated is a biopharmaceutical company focused on developing and commercializing novel therapeutics for dermatologic and aesthetic conditions. The company's pipeline includes treatments for pattern hair loss (VDPHL01), common warts (VDMN), alopecia areata (VDAA), and molluscum contagiosum (VDMC).
What are the main risks for MANE?
Veradermics, Incorporated faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as the company's success depends on the efficacy and safety of its drug candidates. Regulatory hurdles and delays in drug approval can also impact the company's timeline and financial performance. Competition from established pharmaceutical companies with greater resources poses a threat.
What are the key factors to evaluate for MANE?
Veradermics, Incorporated (MANE) holds an AI score of 59/100 (moderate). Not financial advice.
How frequently does MANE data refresh on this page?
MANE's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MANE's recent stock price performance?
Veradermics, Incorporated (MANE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug candidates targeting unmet needs in dermatology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MANE overvalued or undervalued right now?
Veradermics, Incorporated (MANE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MANE before investing?
Before investing in Veradermics, Incorporated (MANE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MANE to a portfolio?
Key strength of Veradermics, Incorporated (MANE): Novel drug candidates targeting unmet needs in dermatology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited to market cap and P/E ratio.
- AI analysis is pending, which limits the depth of analyst perspectives.